Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Elevated miR-200 boosts survival of lung, ovarian, renal, triple-negative breast cancer patients

A family of microRNAs (miR-200) blocks cancer progression and metastasis by stifling a tumor's ability to weave new blood vessels to support itself, researchers at The University of Texas MD Anderson Cancer Center report today in Nature Communications.

12 Sep 2013

FDA grants Breakthrough Therapy designation to Syndax's entinostat for ER+ breast cancer

Syndax Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has designated entinostat as a Breakthrough Therapy for the treatment of locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer when added to exemestane in postmenopausal women whose disease has progressed following non-steroidal aromatase inhibitor therapy.

12 Sep 2013

Ventana gets CFDA approval for VENTANA ALK immunohistochemistry assay

Ventana Medical Systems, Inc., a member of the Roche Group, today announced the approval of the VENTANA ALK immunohistochemistry assay by the Chinese Food and Drug Administration as a companion diagnostic to aid in the identification of patients for Pfizer's CFDA-approved oncology product XALKORI (crizotinib).

12 Sep 2013

Roche Signs Up To $422.5M Collaboration With Inovio

...

10 Sep 2013

Pemetrexed-erlotinib shows second-line efficacy in advanced NSCLC

Combination therapy with pemetrexed and erlotinib significantly improves progression-free survival as compared with either drug alone in patients with advanced non-squamous non-small-cell lung cancer, a phase II study has found.

9 Sep 2013

FDA approves use of abraxane to treat patients with late-stage pancreatic cancer

The U.S. Food and Drug Administration today expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, ablumin-bound) to treat patients with late-stage (metastatic) pancreatic cancer.

7 Sep 2013

Prophylactic cranial irradiation beneficial in elderly SCLC patients

Prophylactic cranial irradiation improves survival in elderly patients with limited-stage small-cell lung cancer, analysis of US epidemiologic data indicates.

6 Sep 2013

Chemotherapy best second-line option for EGFR wild-type NSCLC

Chemotherapy is more effective than erlotinib as second-line therapy in people with advanced non-small-cell lung cancer and wild-type epidermal growth factor receptor genotype, a randomized controlled trial has found.

5 Sep 2013

Study shows benefit of chemotherapy on survival of elderly patients with SCLC

Although numerous randomized clinical trials have demonstrated a benefit of chemotherapy for patients with small-cell lung cancer (SCLC), these trials have predominantly compared different chemotherapy regimens rather than comparing chemotherapy to best supportive care. Some of them included chest radiation or prophylactic cranial irradiation. Moreover, many trials excluded elderly patients.

5 Sep 2013

Latest study recommends accelerated radiotherapy for un-resected NSCLC patients

Radiotherapy with or without chemotherapy is increasingly being used in the curative treatment for un-resected non-small cell lung cancer (NSCLC). But, until now, researchers had not looked at the cost-effectiveness of the treatment.

5 Sep 2013

Findings establish gene as critical regulator of lung cancer tumor growth

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have shown that a well-known cancer-causing gene implicated in a number of malignancies plays a far more critical role in non-small cell lung cancer, the most common form of the disease, than previously thought.

30 Aug 2013

Albumin-bound paclitaxel has favorable risk–benefit profile in NSCLC

Albumin-bound paclitaxel plus carboplatin is an effective and well-tolerated first-line treatment in patients with advanced non-small-cell lung cancer, irrespective of histology, study results show.

29 Aug 2013

CST introduces HER3 antibody for studying HER2-mediated breast, lung and ovarian tumors

Cell Signaling Technology, Inc. of Danvers, MA, announced today that it has introduced a highly specific HER3 rabbit monoclonal antibody (mAb), an important addition for researchers studying HER2-mediated breast, lung and ovarian tumors.

From Cell Signaling Technology 28 Aug 2013

FDA grants Priority Review designation to sNDA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted Priority Review designation to the supplemental New Drug Application for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets under evaluation for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

27 Aug 2013

Four genetic variants in non-small cell lung cancer patients help predict survival, treatment response

Researchers at the Moffitt Cancer Center have identified four inherited genetic variants in non-small cell lung cancer patients that can help predict survival and treatment response. Their findings could help lead to more personalized treatment options and improved outcomes for patients.

9 Aug 2013

Specific pattern in lung tumor pathology is strong predictor of recurrence, says study

A new study by thoracic surgeons and pathologists at Memorial Sloan-Kettering Cancer Center shows that a specific pattern found in the tumor pathology of some lung cancer patients is a strong predictor of recurrence.

8 Aug 2013

Compugen, Bayer sign collaboration and license agreement for antibody-based cancer immunotherapies

Compugen Ltd. announced today the signing of a collaboration and license agreement for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen discovered immune checkpoint regulators.

5 Aug 2013

ImmunoGen reports net loss of $21.9 million in Q4 2013

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload antibody-drug conjugate technology, today reported financial results for the three-month period and fiscal year ended June 30, 2013. ImmunoGen also provided guidance for its 2014 fiscal year and an update on the Company.

2 Aug 2013

Phase III trial shows afatinib offers clinical benefit to patients with EGFR mutation positive NSCLC

Afatinib has a novel mode of action and data has shown that it offers a clinical benefit to patients with a specific type of lung cancer, which we are further investigating in the extensive LUX-Lung clinical trial programme.

1 Aug 2013

ALCF honors oncologist with Lectureship Award for ground-breaking work on lung cancer research

The Bonnie J. Addario Lung Cancer Foundation (ALCF) honored Tony Mok, MD, with the 2013 Addario Lectureship Award for his continued ground-breaking work for lung cancer patients, doctors and caregivers around the world. Dr. Mok, of Chinese University of Hong Kong, received the award at the 14th International Lung Cancer Congress held on July 25 in Huntington Beach, California.

29 Jul 2013

Small Cell Lung Cancer News and Research

Elevated miR-200 boosts survival of lung, ovarian, renal, triple-negative breast cancer patients

FDA grants Breakthrough Therapy designation to Syndax's entinostat for ER+ breast cancer

Ventana gets CFDA approval for VENTANA ALK immunohistochemistry assay

Roche Signs Up To $422.5M Collaboration With Inovio

Pemetrexed-erlotinib shows second-line efficacy in advanced NSCLC

FDA approves use of abraxane to treat patients with late-stage pancreatic cancer

Prophylactic cranial irradiation beneficial in elderly SCLC patients

Chemotherapy best second-line option for EGFR wild-type NSCLC

Study shows benefit of chemotherapy on survival of elderly patients with SCLC

Latest study recommends accelerated radiotherapy for un-resected NSCLC patients

Findings establish gene as critical regulator of lung cancer tumor growth

Albumin-bound paclitaxel has favorable risk–benefit profile in NSCLC

CST introduces HER3 antibody for studying HER2-mediated breast, lung and ovarian tumors

FDA grants Priority Review designation to sNDA for Nexavar tablets

Four genetic variants in non-small cell lung cancer patients help predict survival, treatment response

Specific pattern in lung tumor pathology is strong predictor of recurrence, says study

Compugen, Bayer sign collaboration and license agreement for antibody-based cancer immunotherapies

ImmunoGen reports net loss of $21.9 million in Q4 2013

Phase III trial shows afatinib offers clinical benefit to patients with EGFR mutation positive NSCLC

ALCF honors oncologist with Lectureship Award for ground-breaking work on lung cancer research

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News